Rheumatoid arthritis is a chronic disease that leads to inflammation of the joints and surrounding tissues. It can also affect other organs. Vectra® DA is an advanced blood test that helps patients and their doctors to better assess RA disease activity.

Nearly 1.5 million Americans are living with rheumatoid arthritis (RA), a chronic disease that affects women two to three times more often than men. RA is an autoimmune disease that mainly affects the joints – especially in the hands and feet – but can also have an impact on many other parts of the body, including the heart, lungs and blood vessels. RA causes pain, swelling and redness in the affected joints and, over time, cartilage and bone can wear away, causing increasing pain and eventually leading to disability.

Patients and Physicians Work Together to Manage RA

Stephanie talks about how she has taken control of her life by tracking her disease and partnering with her rheumatologist.

Managing Rheumatoid Arthritis

Regular, objective assessments of RA disease activity are key to achieving target levels of disease activity and improving patient outcomes.1-7 Management of RA is largely informed by assessments of clinical symptoms, joint evaluations and laboratory testing for C-reactive protein (CRP) and/or erythrocyte sedimentation rate (ESR). However, these measures cannot always identify underlying disease activity or assess the risk of future structural damage, which may continue even when signs and symptoms appear to be controlled.8-10

Using Blood Tests to Monitor RA Disease Activity

RA is a disease that involves complex interactions among multiple proteins in a number of tissues, including bone, cartilage and synovium.11 Vectra® DA is a multi-biomarker blood test that simultaneously measures 12 key biomarkers consistently associated with RA disease activity and combines them in a single score between 1 and 100. By providing an objective and reproducible measure of RA disease activity that can be used to complement existing assessment tools, Vectra DA provides an objective and reproducible measure of RA disease activity that can be used to complement existing assessment tools.12,13

References

1. Grigor C, et al. Effect of a treatment strategy of tight control for rheumatoid arthritis (the TICORA study): a single-blind randomised controlled trial. Lancet. 2004;364:263-269.

2. Rantalaiho V, et al, for the FIN-RACo Trial Group. Early combination disease-modifying antirheumatic drug therapy and tight disease control improve long-term radiologic outcome in patients with early rheumatoid arthritis: the 11-year results of the Finnish Rheumatoid Arthritis Combination Therapy trial. Arthritis Res Ther. 2010;12(3):R122.

3. Verstappen SMM, et al. Intensive treatment with methotrexate in early rheumatoid arthritis: aiming for remission. Computer Assisted Management in Early Rheumatoid Arthritis (CAMERA, an open-label strategy trial). Ann Rheum Dis. 2007;66:1443-1449.

4. Goekoop-Ruiterman YPM, et al. Clinical and radiographic outcomes of four different treatment strategies in patients with early rheumatoid arthritis (the BeSt study): a randomized, controlled trial. Arthritis Rheum. 2005;52:3381-3390.

5. Saag KG, et al. American College of Rheumatology 2008 recommendations for the use of nonbiologic and biologic disease-modifying antirheumatic drugs in rheumatoid arthritis. Arthritis Rheum. 2008;59:762-784.

6. Combe B, et al. EULAR recommendations for the management of early arthritis: report of a task force of the European Standing Committee for International Clinical Studies Including Therapeutics (ESCISIT). Ann Rheum Dis. 2007;66:34-45.

7. Smolen JS, et al. Treating rheumatoid arthritis to target: recommendations of an international task force. Ann Rheum Dis. 2010;69:631-637.

8. Barton JL, et al. Patient-physician discordance in assessments of global disease severity in rheumatoid arthritis. Arthritis Care Res. 2010;62:857-864.

9. Sokka T, Pincus T. Erythrocyte sedimentation rate, C-reactive protein, or rheumatoid factor are normal at presentation in 35%–45% of patients with rheumatoid arthritis seen between 1980 and 2004: analyses from Finland and the United States. J Rheumatol. 2009;36:1387-1390.

10. Brown AK, et al. An explanation for the apparent dissociation between clinical remission and continued structural deterioration in rheumatoid arthritis. Arthritis Rheum. 2008;58:2958-2967.

11. Garnero P, Geusens P, Landewé R. Biochemical markers of joint tissue turnover in early rheumatoid arthritis. Clin Exp Rheumatol. 2003:21(suppl 31):S54-S58.

12. Curtis JR, et al. Validation of a novel multi-biomarker test to assess rheumatoid arthritis disease activity. Arthritis Care & Research. 2012; 64 (12):1794-1803.

13. Hambardzumyan K, et al. Pre-treatment multi-biomarker disease activity score and radiographic progression in early RA: results from the SWEFOT trial. Ann Rheum Dis 2014. doi:10.1136/annrheumdis-2013-204986